The companies hope to be as efficacious as ex vivo therapy, with convenience and safety advantages.

The company stops dosing in the troubled Tamarack trial, and is going quiet until ESMO.

But the company hasn’t given details, and used a historical control rather than the study’s own control arm.

Meanwhile, the RayzeBio-originated RYZ101 is back in Action.

But Imfinzi's precise setting is uncertain, and big problems loom for companies pursuing similar trials.